Literature DB >> 8519686

Regulation of ornithine decarboxylase mRNA levels in human breast cancer cells: pattern of expression and involvement of core enhancer promoter element.

P S Wright1, J R Cooper, D E Cross-Doersen, J A Miller, P A Chmielewski, R L Wagner, K A Streng, M A Flanagan.   

Abstract

Ornithine decarboxylase (ODC) expression is increased by growth factors and is obligatory for progression through the cell cycle in a wide variety of cell types. In this study, a variant human ODC cDNA was identified, sequenced, and used to probe mRNA levels in human breast tumor cell lines and xenografts. ODC mRNA was elevated about 3-fold in estrogen receptor-negative (ER-) tumors (MDA-MB-231) when compared with ER-positive (ER+) tumors (MCF-7), as assessed by quantitative autoradiographic analysis of in situ hybridization experiments. The pattern of ODC mRNA in MDA-MB-231 (ER-) xenografts was polarized to the extreme periphery of the tumor, whereas the distribution of ODC mRNA was more evenly distributed in MCF-7 (ER+) xenografts. This correlates with hematoxylin and eosin staining patterns, suggesting that ER+ and ER- xenografts have a differential dependence on host vasculature for growth factor supply. ODC mRNA was elevated 5-fold in MDA-MB-231 cells versus MCF-7 cells when analyzed in cell culture. These relative mRNA levels correlate with increased levels of "core" enhancer binding nuclear proteins in MDA-MB-231 cells over that detected in MCF-7 cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8519686

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  2 in total

1.  Interferon alpha2 recombinant and epidermal growth factor modulate proliferation and hypusine synthesis in human epidermoid cancer KB cells.

Authors:  M Caraglia; A Passeggio; S Beninati; A Leardi; L Nicolini; S Improta; A Pinto; A R Bianco; P Tagliaferri; A Abbruzzese
Journal:  Biochem J       Date:  1997-06-15       Impact factor: 3.857

2.  Tissue-based assay for ornithine decarboxylase to identify patients likely to respond to difluoromethylornithine.

Authors:  Victor A Levin; Jacob L Jochec; Lisa M Shantz; Patricia E Koch; Anthony E Pegg
Journal:  J Histochem Cytochem       Date:  2004-11       Impact factor: 2.479

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.